Stocks gained Monday, with the S&P 500 and Nasdaq Composite each rising over 1%, as investors remained hopeful that the ...

(Reuters) -Shares of Metsera fell over 15% in premarket trading on Monday, after the weight-loss drug developer accepted a ...

Metsera said it has struck a revised merger agreement with Pfizer that values the company at up to $86.25 per share in cash.

The months-long bidding war for obesity drugmaker Metsera came to an end late Friday, but not before federal regulators ...

Pfizer's agreement to buy Metsera just adds to the 83 healthcare deals counted by Goldman Sachs that were above $100 million ...

Shares climbed as much as 3.5% in early European trade after Pfizer agreed to buy Metsera in a deal that could be worth more ...

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.

The contract chip maker's sales rose last month at the slowest pace since February 2024, but [remained in double-digits]( ...

Pharma giant had to pay a blockbuster price to buy Metsera after the biotech prospect spurred an auction with Novo Nordisk ...

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...

Pfizer Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

“No need for a reunion show: This seasons Real Housewives of Biopharma comes to a close with Pfizer’s winning bid for Metsera ...